WHO Declares H1N1 Virus Outbreak a Pandemic
U.S. Department of Health and Human Services Secretary Kathleen Sebelius and U.S. Department of Homeland Security Secretary Janet Napolitano issued the following statements today in response to the World Health Organization’s (WHO) decision to raise the pandemic threat level on the novel H1N1 virus.
“Today’s decision by the WHO was expected and doesn’t change what we have been doing here in the United States to prepare for and respond to this public health challenge. Once we saw how fast this virus was spreading, we activated our pandemic plans and started doing all the things we needed to do to keep the public as safe and secure as possible,” said Secretary Sebelius. “What this declaration does do is remind the world that flu viruses like H1N1 need to be taken seriously. Although we have not seen large numbers of severe cases in this country so far, things could possibly be very different in the fall, especially if things change in the Southern Hemisphere, and we need to start preparing now in order to be ready for a possible H1N1 immunization campaign starting in late September.”
Swine Flu Virus Prevention:
Skinvisible’s DermSafe chlorhexidine hand sanitizer has been tested against many bacteria and viruses. It has been proven to kill / inactivate a number of influenza A viruses; including a strain of H1N1; the swine flu virus. Click here to read more...
Skinvisible in the News:
CBS News Station: Watch the television news cast featuring
SKINVISIBLE’S DERMSAFE AND HOW IT PROTECTS AGAINST H1N1
Read the newspaper article featuring
DERMSAFE MADE BY SKINVISIBLE
Skinvisible Pharmaceuticals, Inc.
Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products,
alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®. Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products. Click here to see current licensees.
The Technology: Invisicare® offers numerous benefits including binding products to the skin for 4 hours+ and more, while resisting wash-off and rub-off. It also enhances the efficacy of ingredients, reduces irritation and can reduce costs. Skinvisible has developed a portfolio of 25+ skincare products using Invisicare and also works directly with companies to enhance their products, especially ones coming off patent. Learn more at www.invisicare.com .
Intellectual Property: Skinvisible's value lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. Patent approvals are sought (in the U.S. and internationally) for all products developed. There are 4 patents approved, 9 U.S. patents pending in addition to 34 PCTs internationally, with many more to be filed. Some of these PCT patents cover up to five products. All patents with Invisicare are owned by Skinvisible. Click here to learn more about our patents.
The Opportunity: New product formulations are expensive and time intensive. Pharmaceutical companies are pursuing new or improved revenue streams along with protecting their own IPs. Invisicare allows companies to sell a patent-protected product that has been revitalized with new benefits, providing a new story to help combat generic competitors. An Rx dermatology product can generate $100+ million per year; many even more - that's why a pharmaceutical company's investment into an Invisicare formulated product is a very viable option.
|
The Analyst Report
February 2, 2009
February 25, 2008
July 21, 2008
Latest News:
June 25, 2009, 2009
Skinvisible Receives Comprehensive Patent in China
- Patent Protection For Invisicare Expands
May 4, 2009
Skinvisible in the News re H1N1
April 28, 2009
Skinvisible's DermSafe® Hand Sanitizer Kills Swine Flu Virus
- Prevention Available to Combat Spread of Viruses
CLICK HERE TO READ ALL NEWS RELEASES
|
Skinvisible Web
